Vistamycinに関する基礎的, 臨床的研究

DOI Web Site

書誌事項

タイトル別名
  • THE FUNDAMENTAL AND CLINICAL STUDIES ON VISTAMYCIN
  • Vistamycin ニ カンスル キソテキ , リンショウテキ ケンキュウ

この論文をさがす

抄録

Fundamental and clinical evaluations of a new aminoglucoside antibiotic, Vistamycin, were performed. The results obtained are as follows : <BR>1) In vitro antibacterial activity : The minimum inhibitory concentration of Vistamycin was measured by the agar plate dilution method. Vistamycin inhibited the growth of 80 strains of coagulase positive Staphylococcus aureus at 0.78-≥100 mcg/ml. Vistamycin compound also demonstrated the antibacterial effect against Escherichia coli and Proteus vulgaris isolated from clinical specimens. Vistamycin demonstrated thus a broad spectrum of antimicrobial activity.<BR>2) Concentration in blood : The maximal level reached 35.7 mcg/ml on the average 30 minutes after the injection of 500mg to healthy adults, and the level was still 2.8 mcg/ml 6 hours after the injection.<BR>3) Concentration in tissues : Vistamycin activity was demonstrable at the concentration of 6.6 and 6.3 mcg/g in a human palatine tonsilla specimen 1 hour after the injection of 500 mg. The plasma levels of Vistamycin were then 30.5 and 28.3 mcg/ml.<BR>4) Clinical evaluation : In the clinical test of Vistamycin on otorhinolaryngological infections, it was found that the results were good to excellent in as many as 27 of 33 cases (82%) by the injection or local application of 10 mg/ml solution.<BR>5) Side effect : The comparative examination of liver, electrocyte and audiogram before and after injection showed no significant disturbance. No side effect was shown with the injection or local application of Vistamycin.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ